Clinical Trials | April 15, 2024
Teva confirms efficacy and safety of Ajovy for prevention of migraine
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
_256_384.jpg)
This facility manufactures APIs & formulations of oncology and non-oncology products.
The inspection was conducted from April 8 to April 12, 2024 and concluded with no observations
A significant proportion of healthcare professionals still tend to favor branded drugs
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
The company will respond to the Warning Letter within the stipulated timelines
Empowering Research, Enhancing Proficiency is the theme of this year’s Homoeopathic Symposium
A game changing solution for the pharmaceutical industry
Highly effective preservation solutions ensuring the safety and protection of personal care products
Subscribe To Our Newsletter & Stay Updated
